Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimizing MATRix as Remission Induction in PCNSL: De-escalated Induction Treatment in Newly Diagnosed Primary CNS Lymphoma - a Randomized Phase III Trial

NCT04931368 is registered in ClinicalTrials.gov with Klinikum Stuttgart as lead sponsor.

NCT NCT04931368
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04931368 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimizing MATRix as Remission Induction in PCNSL: De-escalated Induction Treatment in Newly Diagnosed Primary CNS Lymphoma - a Randomized Phase III Trial
Lead sponsor
Klinikum Stuttgart
Phase
Phase 3
Overall status
Active, not recruiting
Start date
June 28, 2021
Completion date
November 30, 2028
Enrollment
331 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

primary central nervous system lymphoma